Skip to main content
. 2020 Sep 24;10:559896. doi: 10.3389/fonc.2020.559896

FIGURE 6.

FIGURE 6

Low tumor mutational burden and high copy number alteration together predict a poor response to immune checkpoint inhibitor therapy. (A,B) Low TMB and high CNA show shorter progression-free survival in patients receiving ICI (PD-1/L1 inhibitor or in combination with anti-CTLA-4) (A) and patients receiving PD-1/PD-L1 inhibitor alone (B). (C,D) Low TMB and high CAN show decreased proportion of DCB in patients receiving ICI (PD-1/L1 inhibitor or in combination with anti-CTLA-4) (C) and patients receiving PD-1/PD-L1 inhibitor alone (D). (E,F) Low TMB and high CNA show shorter progression-free survival in KRAS-mutant patients receiving ICI (PD-1/L1 inhibitor or in combination with anti-CTLA-4) (E) and KRAS-mutant patients receiving PD-1/L1 inhibitor alone (F). (G,H) Low TMB and high CNA show decreased proportion of DCB in KRAS-mutant patients receiving ICI (PD-1/L1 inhibitor or in combination with anti-CTLA-4) (G) and KRAS-mutant patients receiving PD-1/L1 inhibitor alone (H). MUT, mutant; WT, wild-type; DCB, durable clinical benefit; NDB, no durable clinical benefit.